- Home
- SMID vs FBRX Comparison
SMID vs FBRX Comparison
Compare SMID & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMID
- FBRX
- Stock Information
- Founded
- SMID 1960
- FBRX N/A
- Country
- SMID United States
- FBRX United States
- Employees
- SMID N/A
- FBRX N/A
- Industry
- SMID Building Materials
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- SMID Industrials
- FBRX Health Care
- Exchange
- SMID Nasdaq
- FBRX Nasdaq
- Market Cap
- SMID 229.0M
- FBRX 154.5M
- IPO Year
- SMID 1995
- FBRX N/A
- Fundamental
- Price
- SMID $41.06
- FBRX $11.05
- Analyst Decision
- SMID
- FBRX Strong Buy
- Analyst Count
- SMID 0
- FBRX 3
- Target Price
- SMID N/A
- FBRX $68.00
- AVG Volume (30 Days)
- SMID 12.1K
- FBRX 79.2K
- Earning Date
- SMID 08-14-2025
- FBRX 08-14-2025
- Dividend Yield
- SMID N/A
- FBRX N/A
- EPS Growth
- SMID 162.25
- FBRX N/A
- EPS
- SMID 2.27
- FBRX N/A
- Revenue
- SMID $90,998,000.00
- FBRX N/A
- Revenue This Year
- SMID N/A
- FBRX N/A
- Revenue Next Year
- SMID N/A
- FBRX N/A
- P/E Ratio
- SMID $18.99
- FBRX N/A
- Revenue Growth
- SMID 32.97
- FBRX N/A
- 52 Week Low
- SMID $25.13
- FBRX $4.11
- 52 Week High
- SMID $51.96
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- SMID 55.38
- FBRX 50.28
- Support Level
- SMID $39.36
- FBRX $10.73
- Resistance Level
- SMID $43.52
- FBRX $11.79
- Average True Range (ATR)
- SMID 2.03
- FBRX 1.02
- MACD
- SMID -0.09
- FBRX -0.01
- Stochastic Oscillator
- SMID 54.39
- FBRX 30.65
About SMID Smith-Midland Corporation
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).